TC BioPharm (TCBP) filed a registration statement with the US Securities and Exchange Commission Wednesday for the potential sale of up to $100 million of securities from time to time in one or more offerings.
The filing covers the sale of the company's American depositary shares representing ordinary shares, debt securities, warrants, rights, and units.
Proceeds from the offering will be used for drug discovery and development programs and general corporate purposes, including working capital, market awareness, capital expenditures, investments, acquisitions, and collaborations, according to the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.